Lantheus Holdings Inc - ESG Rating & Company Profile powered by AI
The webpage of Lantheus Holdings Inc was prepared by All Street Sevva using leading artificial intelligence. Browse to the end of this page for potential risks for Lantheus Holdings Inc based on industry, geography and marketcap. This page contains a Q&A section on Lantheus Holdings Inc.
Lantheus Holdings Inc in the Medical Equipment, Supplies & Distribution industry gained a UN SDG ESG Transparency Score of 5.5; made up of an environmental score of 4.8, social score of 5.3 and governance score of 6.4.
5.5
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Bioteque Corp | 8.0 | High |
1 | Amplitude Surgical SA | 8.0 | High |
129 | Vivos Therapeutics Inc | 5.6 | High |
129 | Xvivo Perfusion AB | 5.6 | High |
135 | Lantheus Holdings Inc | 5.5 | High |
135 | AK Medical Holdings Ltd | 5.5 | High |
135 | Paxman AB (publ) | 5.5 | High |
... | ... | ... | |
380 | ZoomMed Inc | 0.0 | Low |
380 | iRay Technology Co Ltd | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Lantheus Holdings Inc have an accelerator or VC vehicle to help deliver innovation?
Does Lantheus Holdings Inc disclose current and historical energy intensity?
Does Lantheus Holdings Inc report the average age of the workforce?
Does Lantheus Holdings Inc reference operational or capital allocation in relation to climate change?
Does Lantheus Holdings Inc disclose its ethnicity pay gap?
Does Lantheus Holdings Inc disclose cybersecurity risks?
Does Lantheus Holdings Inc offer flexible work?
Does Lantheus Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Lantheus Holdings Inc disclose the number of employees in R&D functions?
Does Lantheus Holdings Inc conduct supply chain audits?
Does Lantheus Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Lantheus Holdings Inc conduct 360 degree staff reviews?
Does Lantheus Holdings Inc disclose the individual responsible for D&I?
Does Lantheus Holdings Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Lantheus Holdings Inc disclose current and / or historical scope 2 emissions?
Does Lantheus Holdings Inc disclose water use targets?
Does Lantheus Holdings Inc have careers partnerships with academic institutions?
Did Lantheus Holdings Inc have a product recall in the last two years?
Does Lantheus Holdings Inc disclose incidents of discrimination?
Does Lantheus Holdings Inc allow for Work Councils/Collective Agreements to be formed?
Has Lantheus Holdings Inc issued a profit warning in the past 24 months?
Does Lantheus Holdings Inc disclose parental leave metrics?
Does Lantheus Holdings Inc disclose climate scenario or pathway analysis?
Does Lantheus Holdings Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Lantheus Holdings Inc disclose the pay ratio of women to men?
Does Lantheus Holdings Inc support suppliers with sustainability related research and development?
Does Lantheus Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Lantheus Holdings Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Lantheus Holdings Inc involved in embryonic stem cell research?
Does Lantheus Holdings Inc disclose GHG and Air Emissions intensity?
Does Lantheus Holdings Inc disclose its waste policy?
Does Lantheus Holdings Inc report according to TCFD requirements?
Does Lantheus Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Lantheus Holdings Inc disclose energy use targets?
Does Lantheus Holdings Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Lantheus Holdings Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Lantheus Holdings Inc
These potential risks are based on the size, segment and geographies of the company.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.